Table 2.

Clinicopathologic features of patients undergoing Radical Prostatectomy (RP).

N	Age (yr)	PSA (ng/mL)	Clinical T-stage	MRI T-stage	Biopsy GG	RP specimen pathologic features					Recurrence	Adjuvant treatment
						RP GG	Margins	TV (%)	IDC-P	Pathologic T-stage
1	67	6.2	1c	2	3	2	Negative	5	Present	2c	No	No
2	67	11	2b	2	3	3	Negative	10	Present	2c	Yes	ADT
3	59	3.4	2c	2	4	4	Positive	30	Present	3a	Yes	Salvage radiotherapy
4	67	5.9	2c	2	4	4	Negative	10	Present	2c	Yes	ADT
5	65	6.72	1c	3	3	3	Positive	40	Present	3a	Yes	Salvage radiotherapy
6	61	6.1	1c	2	4	4	Positive	30	Present	3a	No	No
7	68	6.9	1c	2	4	4	Negative	15	Present	2c	Yes	PSA surveillance
8	73	2.5	3a	2	3	3	Negative	5	Present	2c	No	No
Mean	67	6.15

ADT, androgen deprivation therapy; GG, ISUP grade group; IDC-P, intraductal carcinoma of the prostate; MRI, magnetic resonance imaging; PSA, prostate-specific antigen; RP, radical prostatectomy, TV, tumor volume.